Biostage (QB) Stock Price

1.20 (25.0%)
Volume 14,021
Bid Price 6.00
Ask Price 6.25
News -
Day High 6.00


52 Week Range


Day Low 5.70
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Biostage Inc (QB) BSTG OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
1.20 25.0% 6.00 13:57:02
Open Price Low Price High Price Close Price Prev Close
5.95 5.70 6.00 4.80
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
29 14,021 $ 5.9756 $ 83,784 - 1.21 - 6.80
Last Trade Time Type Quantity Stock Price Currency
14:48:32 10 $ 6.02 USD


Draw Mode:

Biostage Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 69.69M 11.62M 1.91M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
5.12k $ - - - -

more financials information »

Biostage (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BSTG Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.506.024.484.646931.5033.33%
1 Month4.736.024.304.524771.2726.85%
3 Months5.886.804.305.782,1980.122.04%
6 Months2.336.802.334.733,3313.67157.51%
1 Year1.506.801.213.654,0154.50300.0%
3 Years2.156.800.552.683,2543.85179.07%
5 Years0.14186.800.05260.295475147,1225.864,131.31%

Biostage (QB) Description

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines the synthetic scaffold with tissue engineering and cell biology to create method of addressing organ damage. Its Cellframe technology stimulates the body's signaling pathways and natural healing process to regenerate and restore organ function. The company is developing organ implants as a platform of being used in the esophagus, trachea, and bronchi. Its implants are being advanced and tested in preclinical collaborative studies with Mayo Clinic and Connecticut Children's Medical Center. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2012 and is headquartered in Holliston, Massachusetts.

Your Recent History
Biostage (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.